Lentivirus Production via HO-2 Depletion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The production of lentiviruses is limited by the inconsistent and low titers of viral particles, which hinder their broad application in biotechnology and pharmaceutical industries, particularly in large-volume production for clinical trials, due to the interference of Heme Oxygenase 2 (HO-2) binding to the group-specific antigen (Gag) of viral proteins, preventing their delivery to plasma membranes for maturation.
Innovation Solution
Inhibiting or preventing HO-2 from binding to the Gag protein by genetic knockdown, pharmaceutical inhibition, or deletion, allowing increased viral particle maturation and production by minimizing HO-2's interference, thereby facilitating the delivery of viral proteins to plasma membranes for assembly and budding.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If HO-2 is present in producer cells, then cellular functions are maintained, but viral particle production is limited due to HO-2 binding to Gag protein
Solution Approach 1:
The patent removes HO-2 from the system by generating producer cells with depleted HO-2 expression through RNA interference or CRISPR-Cas9 gene editing. This extraction of the harmful element (HO-2) eliminates its binding interference with Gag protein, thereby resolving the contradiction between maintaining cellular functions and achieving high viral particle production.
Solution Approach 2:
The patent applies preliminary anti-action by pre-depleting HO-2 expression in producer cells before viral production. By using RNAi or CRISPR-Cas9 to knock down HO-2 levels in advance, the system prevents HO-2 from binding to Gag protein during viral assembly, thus proactively counteracting the harmful effect before it can limit viral particle production.
2Productivity
If HO-2 binding to Gag is prevented, then viral particle maturation and production increase, but cellular metabolic functions may be affected
Solution Approach 1:
The patent applies local quality by selectively depleting HO-2 only in the viral producer cells through targeted RNA interference or CRISPR-Cas9 editing, while leaving other cellular functions intact. This localized modification allows high viral particle production in producer cells without broadly affecting cellular metabolism across all cell types, thus resolving the contradiction between increased viral titer and cellular function stability.
3Productivity
If conventional lentivirus production methods are used, then production process is simple, but viral titers are inconsistent and low
Solution Approach 1:
The patent applies preliminary action by pre-modifying producer cells to have depleted HO-2 expression through RNA interference or CRISPR-Cas9 gene editing before viral production. This preliminary preparation ensures that when viral proteins are expressed and assembled, HO-2 is already absent to prevent binding interference, thereby consistently achieving high viral titers without adding complexity to the actual viral production process.
Data Source
AI summary
Increased viral particle maturation and production can be achieved in various methods for producing viral particles from viral proteins, in general, by inhibiting or preventing Heme Oxygenase 2 (HO-2) from binding to the group-specific antigen (Gag) of the viral proteins, thus allowing delivery of the viral proteins to plasma membranes where they can replicate and mature without interference from HO-2. The increase in viral particle maturation and production can also be achieved by minimizing or eliminating the presence of HO-2 to thus reduce or prevent binding of HO-2 to the group-specific antigen (Gag) of the viral proteins. The invention is particularly applicable to the production of lentiviruses from viral proteins wherein the Matrix domain (MA) of the Gag is myristoylated.